Related Experiment Video
Updated: Feb 14, 2026

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
Published on: May 21, 2019
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H Davies1,2, Himisha Beltran3, Amina Zoubeidi1,2
1Vancouver Prostate Centre, 2660 Oak Street, Vancouver, BC, Canada.
Abstract:
The success of next-generation androgen receptor (AR) pathway inhibitors, such as abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by the emergence of drug resistance. This acquired drug resistance is driven, in part, by the ability of prostate cancer cells to change their phenotype to adopt AR-independent pathways for growth and survival. Around one-quarter of resistant prostate tumours comprise cells that have undergone cellular reprogramming to become AR-independent and to acquire a continuum of neuroendocrine characteristics. These highly aggressive and lethal tumours, termed neuroendocrine prostate cancer (NEPC), exhibit reactivation of developmental programmes that are associated with epithelial-mesenchymal plasticity and acquisition of stem-like cell properties. In the past few years, our understanding of the link between lineage plasticity and an emergent NEPC phenotype has considerably increased. This new knowledge can contribute to novel therapeutic modalities that are likely to improve the treatment and clinical management of aggressive prostate cancer.
Insights
Drug resistance in prostate cancer is driven by cells becoming neuroendocrine prostate cancer (NEPC). Understanding this lineage plasticity offers new therapeutic strategies for aggressive disease.
Area of Science:
- Oncology
- Cancer Biology
- Cellular Reprogramming
Background:
- Next-generation androgen receptor (AR) pathway inhibitors show limited success due to acquired drug resistance in prostate cancer.
- Prostate cancer cells can acquire AR-independent growth pathways, leading to treatment failure.
- A significant subset of resistant tumors exhibit neuroendocrine differentiation, forming aggressive neuroendocrine prostate cancer (NEPC).
Purpose of the Study:
- To explore the link between cellular lineage plasticity and the development of neuroendocrine prostate cancer (NEPC).
- To understand the mechanisms driving AR-independent growth and aggressive phenotypes in prostate cancer.
- To identify novel therapeutic targets for treating advanced and resistant prostate cancer.
Main Methods:
- Analysis of resistant prostate tumors with neuroendocrine features.
- Investigation of cellular reprogramming and phenotypic switching in prostate cancer cells.
- Examination of developmental programs associated with epithelial-mesenchymal plasticity and stem-like properties.
Main Results:
- Acquired resistance in prostate cancer involves phenotypic changes towards AR-independent pathways.
- Approximately 25% of resistant prostate tumors show cellular reprogramming towards NEPC.
- NEPC tumors display reactivated developmental programs linked to plasticity and stem-cell characteristics.
Conclusions:
- Lineage plasticity is a key driver in the emergence of aggressive neuroendocrine prostate cancer.
- Understanding these plasticity mechanisms provides a basis for developing novel therapeutic strategies.
- New knowledge on NEPC development can improve treatment and management of advanced prostate cancer.
Related Concept Videos
Plasticity
Plasticizers
Plasticizers function by using surface-active agents to create repulsive electrostatic forces between cement particles. This dispersion enhances the concrete's...
Plastic Behavior
Plastic Deformations
Plastic Deformations
Plastic Deformation in Circular Shafts

